Rolf Kramer1, Antoine Duclos2, Bruno Lina3, Jean-Sebastien Casalegno4. 1. Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; European Public Health Microbiology Training Programme (EUPHEM), European Centre for Disease Prevention and Control, Stockholm, Sweden. 2. Hospices Civils de Lyon, Pôle de Santé Publique, Service des Données de Santé, Lyon F-69003, France; Université de Lyon, Université Lyon 1, Health Services and Performance Research Lab (HESPER EA7425), F-69008 Lyon, France. 3. Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Hospices Civils de Lyon, National Influenza Centre (South of France), Laboratory of Virology - Bât A3, 59 Boulevard Pinel, F-69677 Bron Cedex, France; Université de Lyon, Université Lyon 1, Virologie et Pathologie Humaine, CNRS FRE 3011, 7 rue Guillaume Paradin, F-69372 Lyon Cedex 08, France. 4. Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Hospices Civils de Lyon, National Influenza Centre (South of France), Laboratory of Virology - Bât A3, 59 Boulevard Pinel, F-69677 Bron Cedex, France; Université de Lyon, Université Lyon 1, Virologie et Pathologie Humaine, CNRS FRE 3011, 7 rue Guillaume Paradin, F-69372 Lyon Cedex 08, France. Electronic address: jean-sebastien.casalegno@chu-lyon.fr.
Abstract
OBJECTIVES: We aimed to describe direct medical costs of annual RSV-associated hospitalisation in the first year of life. METHODS: Retrospective cohort study in Lyon, France (2012-2016). A case was defined as a laboratory confirmed RSV-infection with hospitalisation in the first year of life. Hospital costs were estimated based on the French version of Diagnosis Related Groups. RESULTS: Overall, 350 cases in 21,930 children were identified. Incidence of RSV-associated hospitalisation in the first year of life per 1000 births was 14.5 (95% CI 13.4-15.6). Related direct medical annual costs were 364,269 €, mostly attributed to children born during the RSV season (231,959 €) and children born premature (108,673 €). CONCLUSION: Medical costs for RSV-associated hospitalisation of newborns are higher for children born premature or born during the RSV season. Prioritised targeting of those groups may facilitate a cost-efficient strategy for the national prevention program.
OBJECTIVES: We aimed to describe direct medical costs of annual RSV-associated hospitalisation in the first year of life. METHODS: Retrospective cohort study in Lyon, France (2012-2016). A case was defined as a laboratory confirmed RSV-infection with hospitalisation in the first year of life. Hospital costs were estimated based on the French version of Diagnosis Related Groups. RESULTS: Overall, 350 cases in 21,930 children were identified. Incidence of RSV-associated hospitalisation in the first year of life per 1000 births was 14.5 (95% CI 13.4-15.6). Related direct medical annual costs were 364,269 €, mostly attributed to children born during the RSV season (231,959 €) and childrenborn premature (108,673 €). CONCLUSION: Medical costs for RSV-associated hospitalisation of newborns are higher for childrenborn premature or born during the RSV season. Prioritised targeting of those groups may facilitate a cost-efficient strategy for the national prevention program.
Authors: Nora Suleiman-Martos; Alberto Caballero-Vázquez; Jose Luis Gómez-Urquiza; Luis Albendín-García; Jose Luis Romero-Béjar; Guillermo A Cañadas-De la Fuente Journal: J Pers Med Date: 2021-05-15
Authors: C Demont; N Petrica; I Bardoulat; S Duret; L Watier; A Chosidow; M Lorrot; A Kieffer; M Lemaitre Journal: BMC Infect Dis Date: 2021-08-02 Impact factor: 3.090